Recent reports linking semaglutide to a lower predicted dementia risk have sparked reader debate over whether the drug's health benefits are driven directly by its metabolic effects or simply by resulting weight loss. Many users share anecdotal evidence suggesting that GLP-1 medications independently improve insulin sensitivity and reduce inflammation even without significant weight reduction. Additionally, the discussion highlights widespread frustration regarding the high out-of-pocket costs and lack of insurance coverage for these treatments.